DV
Dividend Vision

ASMB Stock — Assembly Biosciences Inc

Assembly Biosciences Inc (ASMB)

Updated October 16, 2026.

ASMB is a Stock. Total return is -94.7% over the past 15.8 years, 803.7 points behind SPY at 709.0%.

Assembly Biosciences is a biotechnology company developing therapeutic candidates for viral diseases, with a pipeline focused on treatments for recurrent genital herpes, hepatitis delta virus infection, hepatitis B virus infection, and transplant-associated herpesviruses. The company does not currently pay distributions. Assembly Biosciences operates as a clinical-stage development company and may appeal to growth-oriented investors seeking exposure to emerging antiviral therapies.

ASMB performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.7% over the past 15.8 years, 803.7 points behind SPY at 709.0%. Over the past year its total return — price change plus distributions reinvested — is -30.9%. Its deepest 1-year drawdown was 47.8%.

WindowTotal returnCAGR
1M-21.1%—
3M-22.2%—
6M-31.5%—
YTD-40.9%—
1Y-30.9%—
2Y CAGR—6.90%
3Y CAGR—32.10%
5Y CAGR—-12.50%
10Y CAGR—-17.60%
Since inception (15.8 years)-94.7%-16.90%

ASMB key facts

Asset type
Stock
Asset class
Equity
Inception date
12/17/2010
Distribution frequency
None
Last close
$20.09 (as of 2026-10-16)
Market cap
$409,044,374
Average volume
167734.0
Beta
1.157
Payout ratio
0.0%
P/E ratio
19.32
Forward P/E
500.0
EPS
$1.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ASMB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 47.8%.

Who may consider ASMB — and who may not

It is a weaker fit for investors who need monthly cash flow (ASMB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ASMB

Tagged: Healthcare.

Frequently asked questions

Does ASMB pay monthly?

No. ASMB does not currently distribute.

When does ASMB pay a dividend?

ASMB does not currently distribute.

How has ASMB performed?

Total return is -94.7% over the past 15.8 years, 803.7 points behind SPY at 709.0%. Over the past year its total return — price change plus distributions reinvested — is -30.9%. Its deepest 1-year drawdown was 47.8%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.